What Cannot Get Lost in the Handoff

Capable

Capable improved a drug candidate while its earlier version was heading toward safety testing. Now the team has to decide how much development time a potentially better molecule is worth.

That is an unusually concrete problem for an AI company to bring to its investors. Isaak Freeman and Helena Rose are building Capable around the physical work that gives drug-design models something useful to learn from: making compounds, checking them, testing them and carrying the results into another design.

In an October 16 update, Isaak Freeman disclosed a $38M Seed round from Cathay, Abstract, Fidji Simo, Joe Betts-LaCroix, Andrej Karpathy and others. Capable's careers page identifies Cathay Innovation among its backers. Total funding is now $50M, following the $12M described in its earlier introduction.

The company reports moving from a 2,000-square-foot lab to 22,500 square feet in San Francisco's Mission Bay in about 3 weeks. HOF Capital, Fifty Years and Prod were among its earlier institutional backers. The funding is going into a larger operation for generating the experimental data the models need.

Capable says its discovery setup connects AI design, synthesis, quality control, cell assays and mouse testing in a rapid feedback cycle. Keeping those steps close gives the researchers more chances to investigate a result while the design decision is still fresh. It also gives the company responsibility for the machinery, methods and consistency behind the data.

The sleep program makes that responsibility tangible. Capable reports producing a 180-gram batch of CAPABLE-002 through a contracted manufacturer for preclinical safety work. Meanwhile, the team developed a smaller molecule on the same pathway that it believes might eventually support oral dosing.

Both versions remain development projects. Capable says it can continue the safety study while refining the newer molecule, then decide which version to move toward the clinic. Each option carries its own experiments and development calendar. A faster discovery cycle can make that choice arrive sooner, with more alternatives on the table and more work needed to understand them.

For investors, the asset is taking shape in 2 places: the compounds being developed and the lab that keeps producing evidence about them. Capable is expanding both while its scientists work through a very human research decision: whether to keep advancing the candidate already prepared or spend more time on the one they have just learned how to make.

Salience Labs

The purchase order is where photonics has to become predictable. Salience Labs is building toward that conversation with an optical switch, a foundry partner and a new $125M Series B.

The Oxford company announced the round on October 14, led by Bullhound Capital, whose principal Callum Stewart is joining the board. AMD Ventures and Intel Capital are participating alongside SBI Group, Hudson River Trading and British Business Bank, with returning investors including Applied Ventures, Oxford Science Enterprises, Cambridge Innovation Capital and Silicon Catalyst Ventures.

CEO Vaysh Kewada and CTO Johannes Feldmann co-founded Salience Labs from research rooted in Oxford and Münster. Academic co-founders Harish Bhaskaran and Wolfram Pernice belong in that history too. The company began in 2021; bringing that research into an operator's rack now involves a much larger cast.

Salience builds optical circuit switches designed to connect AI accelerators across racks while keeping the switching path optical. Its OC-32M module combines photonic switching and amplification with electronics, firmware and fiber connectors. Somebody evaluating it gets an integration job they can actually examine, down to a rack-mounted development platform.

The company launched its 32-port switch in March and reports demonstrating a 64-port version at ECOC in September. Its 128- and 256-port designs are still on the roadmap. The engineering progression matters because a customer planning a larger cluster needs to understand how the network can grow with it.

Tower Semiconductor gives that progression a manufacturing route. Their February partnership moved into pre-production using Tower's silicon photonics platforms. Keysight brings another part of the buying conversation: a testing environment intended to help operators validate optical switching against AI workloads.

That is where component performance meets the person responsible for the whole installation. The company publishes device specifications, but the buyer still needs to understand workload behavior, compatibility and supply before changing a network around expensive compute.

The $125M is intended to accelerate deployment, scale volume manufacturing and expand Salience's Silicon Valley presence. Following its $30M Series A in 2025, the next movement runs through the foundry, the test environment and the customer evaluating how light fits into the racks already on the floor.

Intuit / Sequence

Riya Grover built Sequence for the moment a custom contract lands in finance. The customer's pricing has already been negotiated; the invoice still has to make sense.

Intuit has signed an agreement to acquire the London- and New York-based revenue software company, founded in 2021. The October 15 announcement puts Sequence's quoting, billing, collections and revenue recognition inside Intuit's ambitions for Enterprise Suite and QuickBooks Online Advanced. Financial terms remain undisclosed, and closing has not been confirmed.

Grover, Sequence's CEO, built the company with Eamon Jubbawy and Enda Cahill. A $20M Series A led by 645 Ventures in December 2025, with a16z and other backers, helped fund the independent company. Now the proposed acquisition gives that work a route into a much larger financial-software ecosystem serving businesses and accountants.

The commercial problem travels well. Sales offers a usage allowance, a temporary discount or a price that changes when the customer reaches a milestone. Finance inherits the job of making those promises add up. A deal can look excellent in the CRM while the person preparing the invoice is still doing the arithmetic by hand.

Sequence describes AI handling contract intake, invoice review and payment chasing while billing calculations stay deterministic and finance teams retain control. That division matters. Customers can negotiate their terms; the software calculating what they owe has to apply those terms consistently.

Ashley Still, Intuit's EVP and GM for Small Business & Mid-Market, links complex revenue management to the decision to buy an ERP. That gives this agreement a specific commercial purpose: help Intuit serve software and professional-services businesses whose pricing has grown more complicated than their existing finance setup can comfortably handle.

For Grover, who is expected to join Intuit's Mid-Market product organization, the distribution opportunity reaches the accounting firms advising those businesses. The person explaining the books can become part of the conversation about how the next contract gets priced and billed.

Intuit plans an integrated offering after closing. As that work develops, the finance team will still arrive with its negotiated discounts, usage records and exceptions. Sequence's new colleagues will be getting the contracts along with the code.

Rush / Endeavor Health

Gerald "J.P." Gallagher would lead a combined health system bearing the Rush name. Endeavor Health would supply the incoming CEO and an incremental $1B investment, giving Chicago's proposed hospital merger a more interesting division of responsibility than the new sign outside suggests.

Rush University System for Health and Endeavor announced their merger plans on October 14. The proposed system would span 12 hospitals and more than 400 care sites, with over 46,000 employees and clinicians serving more than 2M patients annually across northern Illinois and Northwest Indiana, according to the announcement.

Rush brings its health sciences university and academic care infrastructure. Endeavor brings a community network assembled through the NorthShore and Edward-Elmhurst combination. Joining those resources creates a practical opportunity: specialist expertise and research connected to more of the places where people already receive care.

That connection has ordinary work inside it. Endeavor is already consolidating its patient portals into MyEndeavor, with Edward-Elmhurst and NCH users scheduled to move on November 7. That rollout predates this proposed merger. It gives the larger ambition a useful scale reference: somebody still has to make the appointment, find the record and get a message to the right care team.

Gallagher would become president and CEO upon closing. Dr. Omar Lateef would remain Rush president and CEO through the transaction, then become CEO emeritus and strategic adviser. A 20-member board would have equal representation from both systems, with a Rush-side chair. The leadership handoff and shared governance matter when academic priorities and neighborhood access compete for the same organization's attention.

The $1B is a planned investment in community impact, academics, research and care innovation, rather than a disclosed purchase price. The systems say a significant portion would support community partnerships addressing social determinants of health and underserved populations. How that money reaches those partners deserves as much attention as the hospital count.

Regulatory review and approval remain ahead of an early-2027 closing target. WTTW also reported nurses' concerns about prices and service protection. Those questions belong alongside the access ambition, especially for the teams responsible for getting a patient from a neighborhood appointment to the academic care the combined Rush system wants to bring closer.

Antares Ventures

A deep-tech founder can persuade investors to fund a machine and still need help finding the industrial customer willing to try it. Antares Ventures is building a fund around staying useful through that second conversation.

The Singapore firm has secured more than $50M in cumulative commitments for Antares Ventures I at its second close, announced October 14. The final target is $100M, with fundraising continuing. Family offices, corporate and strategic investors from Southeast Asia, Japan and Korea are backing the vehicle; individual LP names were not disclosed.

Founder and Managing Partner Michael Gryseels brings a career that includes 20 years at McKinsey and a chief digital officer role at CP Group. Together, the partners bring experience across deep-tech investing, technology and corporate strategy, venture operations, investment banking and capital formation. Those backgrounds matter to a strategy asking science to survive contact with an operating business.

Antares sources globally from Seed to Series B and helps companies commercialize across Asia. The firm says Fund I has already invested about $27M in 9 companies. Its holdings include VFlowTech in long-duration storage, IONATE in intelligent transformers, enaDyne in industrial plasma technology and The ePlane Company in electric aircraft.

These founders sell into systems somebody already depends on. A new transformer has to belong inside a power network. A storage installation has to support the infrastructure around it. An industrial customer has to judge the engineering while thinking about integration, reliability and the people who will operate the equipment.

Antares describes its contribution in practical terms: governance, customer development, industrial partnerships, pilots, localization and regional expansion. That puts commercial work inside the investor's proposition. Somebody has to help the founder understand how that customer buys, tests and adopts.

The firm's Beyond Carbon & Silicon framework argues that deep tech becomes decisive when it removes a bottleneck in infrastructure customers already run. It gives the portfolio an organizing idea: new technology has to earn its place in the larger system.

As Antares continues raising Fund I, its founders are already carrying technology toward industrial customers. The value of that regional network will keep taking shape in the pilots, implementation decisions and customer relationships the partners help those companies build.